| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/EPI.10.20 |
| P698 | PubMed publication ID | 22121904 |
| P2093 | author name string | Victoria M Richon | |
| P2860 | cites work | Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents | Q21198868 |
| The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress | Q24301895 | ||
| A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition | Q24321639 | ||
| Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) | Q24681480 | ||
| Lysine acetylation targets protein complexes and co-regulates major cellular functions | Q27860589 | ||
| Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes | Q29398493 | ||
| Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer | Q29615066 | ||
| Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia | Q29616211 | ||
| The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men | Q29619117 | ||
| Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species | Q30434975 | ||
| DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. | Q30931932 | ||
| Chemical phylogenetics of histone deacetylases | Q30977637 | ||
| Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies | Q33369463 | ||
| Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 | ||
| Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study | Q33383828 | ||
| A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer | Q33384180 | ||
| Vorinostat in solid and hematologic malignancies | Q33385544 | ||
| Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma | Q33386566 | ||
| A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy | Q33387793 | ||
| Apoptotic and autophagic cell death induced by histone deacetylase inhibitors | Q33583208 | ||
| Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors | Q33926864 | ||
| Histone deacetylases and cancer: causes and therapies | Q34570082 | ||
| Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications | Q35734509 | ||
| Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer | Q35758280 | ||
| The development of proteasome inhibitors as anticancer drugs | Q35773857 | ||
| Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma | Q35808910 | ||
| Role for histone deacetylase 1 in human tumor cell proliferation | Q35948150 | ||
| A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. | Q35976663 | ||
| DNA methylation and gene silencing in cancer | Q36338042 | ||
| Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma | Q37379984 | ||
| Development of vorinostat: current applications and future perspectives for cancer therapy | Q37381104 | ||
| Enhancing the apoptotic and therapeutic effects of HDAC inhibitors | Q37440094 | ||
| New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer | Q37503780 | ||
| Rational combinations using HDAC inhibitors | Q37512911 | ||
| Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. | Q37550149 | ||
| Novel therapies in the treatment of multiple myeloma | Q37624943 | ||
| Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials | Q37662700 | ||
| Romidepsin for the treatment of cutaneous T-cell lymphoma | Q37686109 | ||
| The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. | Q39725251 | ||
| Vorinostat enhances the antimyeloma effects of melphalan and bortezomib | Q39772257 | ||
| Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed | Q39875582 | ||
| An inactivating mutation in HDAC2 leads to dysregulation of apoptosis mediated by APAF1. | Q39932743 | ||
| Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma | Q39981886 | ||
| HDAC3 overexpression and colon cancer cell proliferation and differentiation | Q40082157 | ||
| Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells | Q40148122 | ||
| Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. | Q40149920 | ||
| Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors | Q40550020 | ||
| Acetylation inactivates the transcriptional repressor BCL6. | Q40694067 | ||
| Expression profile of histone deacetylases 1, 2 and 3 in ovarian cancer tissues | Q43136183 | ||
| Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat | Q43244779 | ||
| A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer | Q43249148 | ||
| Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling | Q43873079 | ||
| Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines | Q44317132 | ||
| The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571. | Q44534289 | ||
| Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells. | Q44659750 | ||
| Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation | Q45223539 | ||
| Epigenetic modifiers: basic understanding and clinical development. | Q45976173 | ||
| Upregulation and nuclear recruitment of HDAC1 in hormone refractory prostate cancer | Q47887517 | ||
| Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma | Q48563190 | ||
| Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. | Q52569752 | ||
| Expression profile of histone deacetylase 1 in gastric cancer tissues. | Q53393798 | ||
| Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA | Q53650118 | ||
| Mutations truncating the EP300 acetylase in human cancers | Q57888722 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 457-465 | |
| P577 | publication date | 2010-06-01 | |
| P1433 | published in | Epigenomics | Q20737165 |
| P1476 | title | Targeting histone deacetylases: development of vorinostat for the treatment of cancer | |
| P478 | volume | 2 |
| Q47709789 | A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target |
| Q39426973 | Abnormalities in alternative splicing of angiogenesis-related genes and their role in HIV-related cancers |
| Q35167535 | Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review |
| Q49724675 | Epigenetic actions of environmental factors and promising drugs for cancer therapy |
| Q38195260 | Epigenetics and oncology |
| Q41153044 | Histone deacetylase inhibitors decrease intra-abdominal adhesions with one intraoperative dose by reducing peritoneal fibrin deposition pathways |
| Q42649800 | Possible involvement of ROS generation in vorinostat pretreatment induced enhancement of the antibacterial activity of ciprofloxacin |
| Q42647696 | Simultaneous NF-κB inhibition and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo. |
| Q34413200 | Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors |
| Q38597973 | Tempol prevents genotoxicity induced by vorinostat: role of oxidative DNA damage. |
| Q64056436 | Transcriptional Suppression of CPI-17 Gene Expression in Vascular Smooth Muscle Cells by Tumor Necrosis Factor, Krüppel-Like Factor 4, and Sp1 Is Associated with Lipopolysaccharide-Induced Vascular Hypocontractility, Hypotension, and Mortality |
| Q39037363 | VPA inhibits renal cancer cell migration by targeting HDAC2 and down-regulating HIF-1α. |
Search more.